This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
8 Nov 2011

Horizon & Promega Ink Predictive Disease Model Pact

The partnership aims to develop next-generation predictive human disease models as they occur in patient tumors.

UK translational genomics company Horizon Discovery Ltd. has established a partnership with Promega Corp. for the delivery of endogenous gene reporting capabilities with Promega’s luciferase and HaloTag reporter technologies, using Horizon’s homologous recombination-based precision genome editing technology (rAAV GENESIS).

 

The partnership aims to develop next-generation predictive human disease models as they occur in patient tumors. To date, Horizon has applied its rAAV gene-editing platform to reconstitute more than 370 cancer mutations and variations in human cell lines that serve as patient-relevant, predictive in vitro models of genetic disease.

 

Additional objectives will be to enable the study of tumor response to anti-cancer treatments in real-time, by offering

Related News